Envestnet Asset Management Inc. Acquires 25,589 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Envestnet Asset Management Inc. raised its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 28.1% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 116,727 shares of the biopharmaceutical company's stock after purchasing an additional 25,589 shares during the period. Envestnet Asset Management Inc. owned 0.11% of Regeneron Pharmaceuticals worth $74,031,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in the company. Rakuten Securities Inc. boosted its holdings in Regeneron Pharmaceuticals by 62.5% in the fourth quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company's stock worth $28,000 after purchasing an additional 15 shares in the last quarter. TD Private Client Wealth LLC increased its holdings in shares of Regeneron Pharmaceuticals by 9.6% during the 4th quarter. TD Private Client Wealth LLC now owns 171 shares of the biopharmaceutical company's stock valued at $122,000 after acquiring an additional 15 shares during the last quarter. Adirondack Trust Co. raised its stake in shares of Regeneron Pharmaceuticals by 4.2% in the 1st quarter. Adirondack Trust Co. now owns 451 shares of the biopharmaceutical company's stock valued at $286,000 after acquiring an additional 18 shares in the last quarter. Prestige Wealth Management Group LLC lifted its holdings in Regeneron Pharmaceuticals by 23.2% in the 4th quarter. Prestige Wealth Management Group LLC now owns 101 shares of the biopharmaceutical company's stock worth $72,000 after purchasing an additional 19 shares during the last quarter. Finally, Kingswood Wealth Advisors LLC grew its holdings in Regeneron Pharmaceuticals by 1.8% during the first quarter. Kingswood Wealth Advisors LLC now owns 1,084 shares of the biopharmaceutical company's stock valued at $681,000 after purchasing an additional 19 shares during the last quarter. Institutional investors and hedge funds own 83.31% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms have weighed in on REGN. Morgan Stanley cut their target price on shares of Regeneron Pharmaceuticals from $755.00 to $754.00 and set an "overweight" rating for the company in a research report on Thursday. Guggenheim reaffirmed a "buy" rating on shares of Regeneron Pharmaceuticals in a research report on Friday, May 30th. Argus cut Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Monday, June 30th. Citigroup dropped their target price on shares of Regeneron Pharmaceuticals from $700.00 to $650.00 and set a "buy" rating on the stock in a research report on Monday, June 2nd. Finally, Wells Fargo & Company downgraded shares of Regeneron Pharmaceuticals from an "overweight" rating to an "equal weight" rating and reduced their price target for the company from $700.00 to $580.00 in a report on Friday, May 30th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating, sixteen have assigned a buy rating and three have issued a strong buy rating to the company's stock. According to data from MarketBeat, Regeneron Pharmaceuticals has a consensus rating of "Moderate Buy" and an average target price of $823.54.

Regeneron Pharmaceuticals Trading Up 1.4%

Shares of NASDAQ:REGN traded up $7.98 during mid-day trading on Friday, reaching $567.74. The stock had a trading volume of 844,505 shares, compared to its average volume of 924,824. Regeneron Pharmaceuticals, Inc. has a twelve month low of $476.49 and a twelve month high of $1,211.20. The company has a current ratio of 4.93, a quick ratio of 4.03 and a debt-to-equity ratio of 0.09. The firm has a market cap of $61.29 billion, a PE ratio of 14.67, a price-to-earnings-growth ratio of 2.08 and a beta of 0.33. The firm has a 50 day simple moving average of $545.98 and a two-hundred day simple moving average of $621.52.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share for the quarter, missing the consensus estimate of $8.83 by ($0.61). Regeneron Pharmaceuticals had a return on equity of 15.27% and a net margin of 31.94%. The business had revenue of $3.03 billion for the quarter, compared to the consensus estimate of $3.40 billion. During the same quarter in the prior year, the firm posted $9.55 earnings per share. The business's revenue was down 3.7% on a year-over-year basis. On average, research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, June 6th. Investors of record on Tuesday, May 20th were paid a dividend of $0.88 per share. The ex-dividend date was Tuesday, May 20th. This represents a $3.52 dividend on an annualized basis and a yield of 0.62%. Regeneron Pharmaceuticals's payout ratio is 8.96%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.